MBX Biosciences, Inc. Common Stock
MBX
Market Cap$0
Close$
$1.47
88.6% downside
Current Fair Value
88.6% downsideOvervalued by 88.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | - |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | - |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About MBX Biosciences, Inc. Common Stock
43 employees
CEO: Mr. Peter Kent Hawryluk MBA MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a ...